OLON, a global pharmaceutical leader, is constructing a new facility in Milan, Italy for the exclusive production of ultra-potent compounds, reinforcing its industry dominance in APIs.
The facility will reach containment level OEB6, with a target occupational exposure limit (OEL) of 10 ng/m3.
The project involves the construction of a new building, including dedicated areas for production, quality control, research and development, and auxiliary facilities.
The facility will have a complete, closed-loop system encompassing synthesis, isolation, drying, and analysis steps.
The subsequent phase will involve finalizing the production line, including the installation of industrial production equipment and the creation of quality control and GMP production areas.
OLON's expertise in handling highly potent APIs positions the company as a reliable supplier capable of integrating containment measures throughout the API development and commercial manufacturing processes.
OLON is well-prepared to capitalize on the evolving oncology market, which is shifting towards niche therapies and precision medicine, presenting new growth opportunities.
The first phase of construction, focused on the payload research and development area, has already begun and is expected to be completed by H1, 2024.